公开(公告)号：EP3923907B1

公开(公告)日：2024-09-25

申请号：EP20704853.9

申请日：2020-02-11

IPC: A61K9/00 ,  A61K9/10 ,  A61K38/17 ,  A61K39/395 ,  A61K47/24 ,  A61K47/26 ,  A61P27/02

CPC classification number: A61P27/02 ,  C07K16/00 ,  C07K16/22 ,  C07K2317/7620130101 ,  C07K2317/2420130101 ,  C07K2319/3020130101 ,  C07K2319/3220130101 ,  A61K2039/50520130101 ,  A61K39/39591 ,  A61K9/0048 ,  A61K9/1688 ,  A61K47/06 ,  A61K47/26 ,  A61K38/179

公开(公告)号：EP4431529A1

公开(公告)日：2024-09-18

申请号：EP22892037.7

申请日：2022-11-10

Applicant: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Inventor： DENG, Lan ,  HUANG, Haomin ,  ZHU, Zhenping ,  LIU, Lifen ,  WANG, Lihua ,  MENG, Yun

IPC: C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  C12N5/10 ,  A61K38/17 ,  A61P17/00 ,  A61P27/02

CPC classification number: A61K38/17 ,  A61P9/00 ,  A61P17/00 ,  A61P17/06 ,  A61P29/00 ,  A61P27/02 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63

Abstract: The present invention relates to the technical field of fusion proteins, and relates in particular to an anti-IL-17/VEGF bifunctional fusion protein and a use thereof. The anti-IL-17/VEGF bifunctional fusion protein comprises an anti-IL-17 antibody and a protein that specifically binds to VEGF The protein that specifically binds to VEGF is VEGFR, and the protein that specifically binds to VEGF is connected to the anti-IL-17 antibody directly or by means of a linker. The anti-IL-17/VEGF bifunctional fusion protein may simultaneously block IL-17 and VEGF signaling pathways, and the anti-IL-17/VEGF bifunctional fusion protein may be used to prepare drugs for treating IL-17 and/or VEGF overexpression.

公开(公告)号：EP3756656B1

公开(公告)日：2024-09-11

申请号：EP20172705.4

申请日：2012-03-30

IPC: A61K9/19 ,  A61K38/48 ,  A61K47/02 ,  A61K47/26 ,  A61K47/20 ,  A61P1/00 ,  A61P1/06 ,  A61P13/00 ,  A61P13/10 ,  A61P17/00 ,  A61P21/00 ,  A61P25/06 ,  A61P27/02

CPC classification number: C12Y304/24069 ,  A61K47/02 ,  A61K47/26 ,  A61K38/4893 ,  A61K9/19 ,  A61K47/20 ,  A61P1/00 ,  A61P1/06 ,  A61P13/00 ,  A61P13/10 ,  A61P17/00 ,  A61P21/00 ,  A61P25/06 ,  A61P27/02 ,  Y02A50/30

公开(公告)号：EP4424327A1

公开(公告)日：2024-09-04

申请号：EP22887119.0

申请日：2022-10-27

Applicant: Biozipcode, Inc.

Inventor： KOJIMA, Hideto ,  KATAGI, Miwako

IPC: A61K45/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/343 ,  A61K31/40 ,  A61K31/506 ,  A61P1/00 ,  A61P3/10 ,  A61P13/12 ,  A61P17/00 ,  A61P25/00 ,  A61P27/02

CPC classification number: A61K31/167 ,  A61K31/343 ,  A61P17/00 ,  A61K31/18 ,  A61P3/10 ,  A61K45/00 ,  A61P1/00 ,  A61P13/12 ,  A61K31/506 ,  A61K31/40 ,  A61P25/00 ,  A61P27/02 ,  A61K31/165

Abstract: The present disclosure provides a novel treatment of diabetes mellitus. The present disclosure provides a treatment of diabetes mellitus by combining control of blood glucose and HDAC regulation. In one embodiment, the present disclosure provides a treatment of diabetes mellitus and/or a disease, disorder, and/or symptom associated with diabetes mellitus by combining control of blood glucose and HDAC regulation. In one embodiment, the diabetes mellitus and/or the disease, disorder, and/or symptom associated with diabetes mellitus is treated by targeting aberrant stem cells through a combination of control of blood glucose and HDAC regulation.

公开(公告)号：EP4422660A1

公开(公告)日：2024-09-04

申请号：EP22886038.3

申请日：2022-10-26

Applicant: Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.

Inventor： LI, Xiaoyi ,  DAI, Xiangrong ,  LI, Gang ,  ZHANG, Guohui ,  JIN, Yixuan

IPC: A61K38/13 ,  A61K9/06 ,  A61P27/02 ,  A61P37/06

CPC classification number: A61K38/13 ,  A61P27/02 ,  A61P37/06 ,  A61K9/06 ,  A61K9/0048

公开(公告)号：EP4385571A3

公开(公告)日：2024-08-28

申请号：EP24171603.4

申请日：2017-09-06

Applicant: Pharmakea, Inc.

Inventor： BAIN, Gretchen ,  EVANS, Jillian Frances ,  MACKENNA, Deidre A. ,  HUTCHINSON, John Howard

IPC: A61K31/4439 ,  C07D401/12 ,  A61P19/00 ,  A61P35/00 ,  A61K31/519 ,  A61P1/16 ,  A61P13/12 ,  A61P37/02 ,  A61P29/00 ,  A61P27/02

CPC classification number: C07D401/12 ,  A61P19/00 ,  A61P35/00 ,  A61K45/06 ,  A61K31/4439 ,  A61P27/02 ,  A61P37/02 ,  A61P1/16 ,  A61P19/02 ,  A61P13/12 ,  A61P29/00 ,  A61K31/519

Abstract: The present invention relates to a compound for use in a method for treating a disease or condition in a mammal that would benefit from inhibition or reduction of LOXL2 activity,
wherein the compound is a small molecule LOXL2 inhibitor that is at least 100 times more selective for inhibiting or binding to LOXL2 than for LOX;
wherein the small molecule LOXL2 inhibitor is:
(R,R)-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pylidin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone or a pharmaceutically acceptable salt or solvate thereof;
and wherein the disease or condition is primary myelofibrosis.

公开(公告)号：EP4417259A2

公开(公告)日：2024-08-21

申请号：EP24174882.1

申请日：2016-09-09

Applicant: The Schepens Eye Research Institute, Inc.

Inventor： Chauhan, Sunil ,  Dana, Reza

IPC: A61P27/02

CPC classification number: C07K14/00 ,  C07K14/4753 ,  A61K38/1833 ,  A61P27/02

Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.

公开(公告)号：EP4303211B1

公开(公告)日：2024-08-21

申请号：EP22290046.6

申请日：2022-07-07

IPC: C07C405/00 ,  A61P27/02 ,  A61P27/06 ,  A61K31/5575

CPC classification number: A61P27/02 ,  A61P27/06 ,  C07C405/0041 ,  C07C2601/0820170501 ,  Y02P20/55

公开(公告)号：EP4404949A1

公开(公告)日：2024-07-31

申请号：EP22872348.2

申请日：2022-09-22

Applicant: Tarsier Pharma Ltd.

Inventor： MILMAN-LEVINSON, Zohar ,  HAIM-LANGFORD, Daphne ,  DEFERT, Olivier

IPC: A61K38/07 ,  A61K45/06 ,  A61K47/54 ,  A61K9/00 ,  A61P27/02

CPC classification number: A61K47/54 ,  A61P27/02 ,  A61K47/64 ,  A61K9/0048 ,  A61K31/14 ,  A61K38/08

公开(公告)号：EP4110781B1

公开(公告)日：2024-07-31

申请号：EP21760609.4

申请日：2021-02-25

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/506 ,  A61P31/00 ,  A61P3/00 ,  A61P25/00 ,  A61P27/02 ,  A61P11/00

CPC classification number: A61P3/00 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/02 ,  A61P31/00 ,  C07D471/04 ,  C07D519/00 ,  Y02P20/55